Outlook Therapeutics, Inc. (OTLK) AI Dilution Summary

OTLK is funding itself through registered offerings: estimated cash was $55,125,967 as of 2026-08-14, rolled forward from $11,242,068 at 2026-06-30 against estimated monthly burn of $4,864,188. Its most recent raise was a public offering closed 2026-08-14, raising $55,000,000.44 gross ($51,100,000 net, the issuer's estimate) from 55,555,556 shares with accompanying warrants.